2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalenceTreatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden
2018
Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival
Tamirisa N, Thomas S, Fayanju O, Greenup R, Rosenberger L, Hyslop T, Hwang E, Plichta J. Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Annals Of Surgical Oncology 2018, 25: 2890-2898. PMID: 29968029, PMCID: PMC6404232, DOI: 10.1245/s10434-018-6595-2.Peer-Reviewed Original ResearchConceptsBreast cancer patientsElderly breast cancer patientsCN0 breast cancerOverall survivalNodal surgeryCancer patientsAxillary surgeryElderly patientsTreatment decisionsBreast cancerCharlson-Deyo comorbidity scoreCN0 breast cancer patientsSurgical lymph node evaluationCox proportional hazards modelAdjuvant therapy decisionsAdjuvant therapy receiptAxillary nodal evaluationLymph node evaluationNational Cancer DatabaseYear of diagnosisWorse overall survivalEstrogen receptor statusLong-term outcomesSubsequent treatment decisionsProportional hazards modelThe Effect of Hospital Volume on Breast Cancer Mortality
Greenup R, Obeng-Gyasi S, Thomas S, Houck K, Lane W, Blitzblau R, Hyslop T, Hwang E. The Effect of Hospital Volume on Breast Cancer Mortality. Annals Of Surgery 2018, 267: 375-381. PMID: 27893532, PMCID: PMC5994238, DOI: 10.1097/sla.0000000000002095.Peer-Reviewed Original ResearchConceptsHigh-volume centersNational Cancer Data BaseHospital volumeVolume centersBreast cancerHazard ratioImproved survivalStage 0Case volumeMultivariable Cox proportional hazards modelsMultidisciplinary breast cancer treatmentMultivariable Cox proportional hazardsSurgeons National Cancer Data BaseCox proportional hazards modelAnnual hospital volumeLess common cancersUnilateral breast cancerBreast cancer mortalityBreast cancer patientsCubic spline analysisLog-rank testBreast cancer treatmentCox proportional hazardsProportional hazards modelHigher case volume
2017
The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients
Cho E, Shammas R, Glener A, Greenup R, Hwang E, Hollenbeck S. The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients. Plastic & Reconstructive Surgery 2017, 140: 1121-1131. PMID: 29176410, DOI: 10.1097/prs.0000000000003841.Peer-Reviewed Original ResearchConceptsBody mass index (BMI) changeAutologous breast reconstructionBody mass index increaseBreast cancer patientsBody mass index (BMI) patternsBreast reconstructionCancer patientsMultivariable regressionNormal baseline body mass indexBaseline body mass indexImmediate autologous breast reconstructionCLINICAL QUESTION/LEVELHigh-risk patientsPropensity-matched pairsBody mass indexRisk of recurrenceWeight management strategiesBaseline obesityAdjuvant therapyTotal patientsMass indexTherapeutic mastectomyMastectomy patientsAutologous reconstructionAuthors' institutionAssociation Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis
Shammas R, Cho E, Glener A, Poveromo L, Mundy L, Greenup R, Blackwell K, Hollenbeck S. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. Journal Of The American College Of Surgeons 2017, 225: 731-739.e1. PMID: 28985927, DOI: 10.1016/j.jamcollsurg.2017.08.023.Peer-Reviewed Original ResearchConceptsPostoperative wound breakdownBreast reconstructionReconstructive complicationsWound breakdownReconstructive operationsPropensity score-matched pairsMastectomy skin flap necrosisDuke University Medical CenterAdministration of trastuzumabPrimary study outcomeSkin flap necrosisLarger tumor sizePost-mastectomy reconstructionBreast reconstruction outcomesOccurrence of hematomaUniversity Medical CenterPertuzumab therapyChemotherapy regimenNeoadjuvant chemotherapyOperative interventionFlap thrombosisTrastuzumab therapySurgical outcomesTumor sizeFlap necrosisCost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer
Gamble C, Havrilesky L, Myers E, Chino J, Hollenbeck S, Plichta J, Kelly Marcom P, Shelley Hwang E, Kauff N, Greenup R. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals Of Surgical Oncology 2017, 24: 3116-3123. PMID: 28699130, PMCID: PMC5990891, DOI: 10.1245/s10434-017-5995-z.Peer-Reviewed Original ResearchConceptsRisk-reducing mastectomyOvarian cancer diagnosisIncremental cost-effectiveness ratioBRCA mutation carriersMonths of lifeMutation carriersMagnetic resonance imagingCancer diagnosisSurvival benefitOvarian cancerMutation statusMost BRCA1/2 mutation carriersThird-party payer perspectiveGreater survival benefitBreast cancer riskBRCA mutation statusBRCA1/2 mutation carriersBRCA2 mutation carriersBRCA2 mutation statusBRCA1 mutation carriersBreast cancer screeningMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioYears of lifeProbabilistic sensitivity analysesBreast Cancer after Augmentation
Cho E, Shammas R, Phillips B, Greenup R, Hwang E, Hollenbeck S. Breast Cancer after Augmentation. Plastic & Reconstructive Surgery 2017, 139: 1240e-1249e. PMID: 28538550, DOI: 10.1097/prs.0000000000003342.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast ImplantationBreast ImplantsBreast NeoplasmsCohort StudiesFemaleFollow-Up StudiesHumansIncidenceLogistic ModelsMammaplastyMastectomyMiddle AgedMultivariate AnalysisPostoperative ComplicationsReference ValuesRetrospective StudiesRisk AssessmentStatistics, NonparametricSurgical FlapsTime FactorsTreatment OutcomeUnited StatesConceptsPrior augmentationBreast cancer stageBreast cancerSubglandular augmentationCancer stageImplant placementCLINICAL QUESTION/LEVELPreferred reconstructive methodAdvanced breast tumorsTwo-stage implant reconstructionInvasive breast cancerBreast cancer screeningBreast cancer diagnosisUndergoing mastectomySubpectoral implantsDuctal carcinomaTherapeutic mastectomyCancer screeningTreatment recommendationsImplant reconstructionSubpectoral augmentationAuthors' institutionBreast augmentationMastectomyBreast tumors
2016
Can Vascular Patterns on Preoperative Magnetic Resonance Imaging Help Predict Skin Necrosis after Nipple-Sparing Mastectomy?
Bahl M, Pien I, Buretta K, Hwang E, Greenup R, Ghate S, Hollenbeck S. Can Vascular Patterns on Preoperative Magnetic Resonance Imaging Help Predict Skin Necrosis after Nipple-Sparing Mastectomy? Journal Of The American College Of Surgeons 2016, 223: 279-285. PMID: 27182036, DOI: 10.1016/j.jamcollsurg.2016.04.045.Peer-Reviewed Original ResearchConceptsNipple-sparing mastectomyNipple-areola complexSkin flap ischemiaBlood supplyFlap ischemiaSingle blood supplyPreoperative magnetic resonance imagingSurgical specimen weightPrevious radiation therapyPreoperative breast MRIDual blood supplyMajority of proceduresMagnetic resonance imagingNSM proceduresPatient demographicsSmoking historySurgical complicationsSurgical factorsSkin necrosisVascular findingsFemale patientsDecreased riskIncision typeSingle institutionMedical recordsSurgeons’ Perspectives of Contralateral Prophylactic Mastectomy
Bellavance E, Peppercorn J, Kronsberg S, Greenup R, Keune J, Lynch J, Collyar D, Magder L, Tilburt J, Hlubocky F, Yao K. Surgeons’ Perspectives of Contralateral Prophylactic Mastectomy. Annals Of Surgical Oncology 2016, 23: 2779-2787. PMID: 27169770, DOI: 10.1245/s10434-016-5253-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAttitude of Health PersonnelComprehensionFemaleGenes, BRCA1Genes, BRCA2HumansMaleMedical OveruseMiddle AgedPatientsPractice Patterns, Physicians'Prophylactic MastectomyRisk AssessmentRisk FactorsSurgical OncologySurveys and QuestionnairesUnilateral Breast NeoplasmsConceptsContralateral prophylactic mastectomyOncologic benefitProphylactic mastectomyBreast cancerBenefits of CPMUnfavorable risk/benefit ratioUse of CPMRisk/benefit ratioAverage-risk patientsDeleterious BRCA mutationsProportion of surgeonsInadequate patient understandingPercent of respondentsMedian ageBRCA mutationsBreast diseaseBreast surgeonsPractice patternsRelative riskPatient understandingCommon reasonMost surgeonsMethodsA surveyPatientsSurgeons
2015
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ
Worni M, Akushevich I, Greenup R, Sarma D, Ryser M, Myers E, Hwang E. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal Of The National Cancer Institute 2015, 107: djv263. PMID: 26424776, PMCID: PMC4707192, DOI: 10.1093/jnci/djv263.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneSEER ProgramSentinel Lymph Node BiopsySurvival AnalysisTreatment OutcomeUnited StatesConceptsOverall survivalTreatment patternsPre-invasive breast cancerSentinel lymph node biopsyCox proportional hazards regressionLocoregional treatment optionsNational treatment trendsEnd Results registryLymph node biopsyBreast cancer outcomesLong-term outcomesProportional hazards regressionPatient selection biasCochran-Armitage trend testInverse probability weightsDCIS patientsNode biopsyBilateral mastectomyDuctal carcinomaHazards regressionCancer outcomesTreatment optionsBreast cancerTreatment trendsLumpectomyEvaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI?
Bahl M, Baker J, Greenup R, Ghate S. Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? Annals Of Surgical Oncology 2015, 22: 435-441. PMID: 26249144, DOI: 10.1245/s10434-015-4792-9.Peer-Reviewed Original ResearchConceptsPathologic nipple dischargeMagnetic resonance imagingNipple dischargeNegative predictive valuePositive predictive valuePredictive valueDiagnostic valueNegative magnetic resonance imagingSpecificity of MRIBreast magnetic resonance imagingEvaluation of patientsValuable additional diagnostic toolRadiology Breast Imaging ReportingBI-RADS 1Data System 4Detection of malignancyAdditional diagnostic toolBreast Imaging ReportingSonographic workupDuct explorationRetrospective reviewSurgical excisionRadiographic findingsDuctal carcinomaSymptomatic populationDiagnostic Value of Ultrasound in Female Patients With Nipple Discharge.
Bahl M, Baker J, Greenup R, Ghate S. Diagnostic Value of Ultrasound in Female Patients With Nipple Discharge. American Journal Of Roentgenology 2015, 205: 203-8. PMID: 26102400, DOI: 10.2214/ajr.14.13354.Peer-Reviewed Original ResearchConceptsPathologic nipple dischargeNipple dischargeInvasive adenocarcinomaSurgical excisionEvaluation of patientsDetection of DCISNormal sonographic findingsSpecificity of mammographySpecificity of ultrasoundUseful diagnostic toolContribution of ultrasoundBilateral mammographyFemale patientsPathologic featuresRadiologic findingsRetrospective reviewDuctal carcinomaSonographic findingsPathologic resultsStudy populationPatientsRoutine evaluationDiagnostic valueAdenocarcinomaUltrasoundA Quantitative Diffuse Reflectance Imaging (QDRI) System for Comprehensive Surveillance of the Morphological Landscape in Breast Tumor Margins
Nichols B, Schindler C, Brown J, Wilke L, Mulvey C, Krieger M, Gallagher J, Geradts J, Greenup R, Von Windheim J, Ramanujam N. A Quantitative Diffuse Reflectance Imaging (QDRI) System for Comprehensive Surveillance of the Morphological Landscape in Breast Tumor Margins. PLOS ONE 2015, 10: e0127525. PMID: 26076123, PMCID: PMC4468201, DOI: 10.1371/journal.pone.0127525.Peer-Reviewed Original ResearchConceptsBreast tumor marginsOptical property mapsDiffuse optical spectroscopyImaging systemWhite LED sourceDiffuse reflectance imagesOptical spectroscopyDistribution function analysisFiber optic probeTurbid mediaEmpirical cumulative distribution function (eCDF) analysisLarge tissue areasLED sourcesScattering coefficientSub-pixel resolutionProbe-tissue interfaceIntra-operative toolMorphological landscapeOptic probeImaging platformTime scalesProperty mapsImproved sensitivityEstimation errorSpectrograph
2013
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E. Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort. Annals Of Surgical Oncology 2013, 20: 3254-3258. PMID: 23975317, DOI: 10.1245/s10434-013-3205-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBRCA mutation prevalenceRace/ethnicityBRCA mutationsGenetic counselingBreast cancerMutation prevalenceGenetic mutationsAfrican AmericansHereditary cancer clinicBRCA mutation statusBRCA genetic mutationPersonalized genetic counselingConclusionsThe prevalenceNCCN guidelinesPrimary outcomeRetrospective reviewTNBC subtypesResultsA totalBRCA2 mutationsCancer clinicMutation statusDemographic dataPrevalenceEthnicity/race
2012
Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
Greenup R, Camp M, Taghian A, Buckley J, Coopey S, Gadd M, Hughes K, Specht M, Smith B. Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals Of Surgical Oncology 2012, 19: 3275-3281. PMID: 22851048, DOI: 10.1245/s10434-012-2546-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularCombined Modality TherapyCosts and Cost AnalysisFemaleFollow-Up StudiesHealth Care CostsHumansMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm InvasivenessPrognosisRetrospective StudiesConceptsWhole breast radiation therapyBreast cancerRT optionsExternal-beam partial breast irradiationLeukemia Group B 9343MethodsAn institutional review boardResultsMedian patient ageCurrent Procedural Terminology codesMedian tumor sizeInvasive ductal cancerSitu breast cancerPartial breast irradiationProcedural Terminology codesRadiation treatment optionsInstitutional review boardC-RTBackgroundRadiation therapyRT regimensBreast conservationDuctal cancerLobular cancerMixed histologyPatient ageRetrospective reviewTumor histology